Physician

Bushra Ajaz, MD

According to 2025 Medicare claims, Bushra Ajaz, MD (NPI: 1063750933) practices internal medicine in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Volusia, FL. This provider's primary affiliated billing organization is MID-FLORIDA CANCER CENTERS LLC (NPI: 1255369955; TIN: 592021436) and primary practice location at 32771-1603.

Ajaz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 430 traditional Medicare patients, billed 66,644 HCPCS/CPT codes, and received $954,094 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,741 prescription claims across 222 beneficiaries totaling $4,377,818 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 26 claims. Open Payments data shows 2 records totaling $152. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $4,648 and ending at $954,094. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $38,938 to $4,377,818. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	44	61	$4,648
2017	265	11,448	$210,928
2018	438	67,742	$859,246
2019	477	68,368	$743,175
2020	377	86,510	$1,254,366
2021	366	87,366	$1,531,930
2022	405	68,104	$874,337
2023	489	65,845	$706,576
2024	430	66,644	$954,094

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	23	52	$38,938
2016	27	44	$34,958
2017	93	247	$280,326
2018	169	1,145	$1,245,091
2019	189	1,233	$2,193,905
2020	186	1,169	$2,144,318
2021	186	1,307	$2,650,003
2022	197	1,567	$4,254,147
2023	216	1,420	$4,750,956
2024	222	1,741	$4,377,818

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	24	$34,056
2020	N/R	27	$40,634
2021	N/R	24	$38,755
2022	N/R	25	$40,805
2023	N/R	23	$37,740
2024	N/R	26	$41,673

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	144	355	$92
80053	Blood test, comprehensive group of blood chemicals	154	299	$10
36415	Insertion of needle into vein for collection of blood sample	208	480	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	220	583	$8
84100	Phosphate level	153	297	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	21	588	$483,126
Lenalidomide	Lenalidomide	32	896	$457,643
Lenvima	Lenvatinib Mesylate	12	360	$296,051
Venclexta	Venetoclax	19	570	$274,503
Revlimid	Lenalidomide	15	420	$265,275

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	13	$37,388
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	13	$4,285

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$152	Novocure Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bushra Ajaz, MD?

Tedicare shows public-source Medicare data for Bushra Ajaz, MD (NPI 1063750933), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bushra Ajaz, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Bushra Ajaz, MD?

Bushra Ajaz, MD is linked to MID-FLORIDA CANCER CENTERS LLC (billing NPI 1255369955) in the available physician profile data.

Does Bushra Ajaz, MD have Open Payments data?

Bushra Ajaz, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.